UBS AM’s Zevra Therapeutics ZVRA Stock Holding History

UBS AM’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.4K	Hold	2,118	–	–	﹤0.01%	3045
2026 Q1	$19.7K	Buy	2,118 +1,568	+285%	+$14.1K	﹤0.01%	3142
2025 Q4	$4.93K	Buy	+550	New	+$5.2K	﹤0.01%	2980

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS AM's ZVRA Position: Q2 2026 in Review

UBS AM held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 2,118 shares worth $30.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3045.

UBS AM first reported a position in ZVRA in Q4 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

UBS AM held 2,118 shares of Zevra Therapeutics worth $30.4K as of Q2 2026.
UBS AM left its Zevra Therapeutics share count unchanged in Q2 2026.
Zevra Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3045 holding.
UBS AM first reported a position in Zevra Therapeutics in Q4 2025 and has held it in 3 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.